南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

表观组学专题:ATAC-seq,你了解多少呢(93546ES)

Recombinant Human B7-2/CD86 (hFc Tag)
分享
收藏
产品详情
FAQ
产品文档
已发表文献
产品应用
产品介绍

B7-2, also known as CD86, B70, and ETC-1, is a 60-100 kDa variably glycosylated protein in the B7 family. B7 family members are transmembrane cell surface molecules that play important roles in immune activation and the maintenance of immune tolerance. Mature human B7-2 consists of a 224 aa extracellular domain (ECD) with two Ig-like domains, a 21 aa transmembrane segment, and a 61 aa cytoplasmic tail. Within the ECD, human B7-2 shares 59% aa sequence identity with mouse and rat B7-2. Alternative splicing of human B7-2 generates additional isoforms that lack both Ig-like domains or a region that includes the transmembrane segment. B7-2 is highly expressed on activated antigen presenting cells (APC), e.g. B cells, dendritic cells, and monocytes, as well as on vascular endothelial cells. B7-2 and the closely related B7-1/CD80 exhibit overlapping but distinct functional properties. Their binding to CD28, which is constitutively expressed on T cells, enhances T cell receptor signaling and also provides TCR-independent co-stimulation. B7-1 and B7-2 additionally bind the CD28-related protein, CTLA-4, which is upregulated and recruited to the immunological synapse (IS) at the onset of T cell activation. CTLA-4 ligation inhibits the T cell response and supports regulatory T cell function. B7-2 is expressed earlier than B7-1 following APC activation, and both proteins bind with higher affinity to CTLA-4 than to CD28. B7-2 promotes the stabilization of CD28 in the IS, while B7-1 is primarily responsible for promoting CTLA-4 recruitment and accumulation in the IS.

产品性质
产品特色

高纯度、高活性、低内毒素、高批间一致性

应用案例
image.png
image.png
存储条件

-25 ~ -15℃保存,收到货之后有效期1年。 复溶后, 无菌条件下,-85 ~ -65℃保存,3个月有效期。

COA
已发表文献
产品应用

【应用方向】BCMA/TNFRSF17:多发性骨髓瘤免疫治疗的核心靶点蛋白

340

2026-08-31

【应用方向】CD20:B细胞恶性肿瘤免疫治疗的核心靶点蛋白

365

2026-08-31

【应用方向】CD19:血液肿瘤免疫治疗的核心靶点蛋白

386

2026-08-31

【文献解读】Science 重磅成果:西湖大学团队攻克共价蛋白药物核心瓶颈,建立通用高通量速效蛋白筛选平台

590

2026-06-25

【技术讲解】信号通路系列 | Wnt/β-catenin信号通路:细胞的“信号转换器”与“命运规划师”

873

2026-04-29

【文献解读】EGFR信号通路的耐药新视角:当EGFR-TKI遇上免疫压力,肿瘤如何“金蝉脱壳”?

692

2026-04-29

【应用方向】免疫检查点核心家族:B7-CD28超家族蛋白

1356

2026-04-21

【应用方向】TIM-3:下一代肿瘤免疫检查点治疗的核心靶点

1030

2026-04-21

【应用方向】SIRP家族分子详解与产品选择指南

848

2026-04-21

【应用方向】OX40-OX40L共刺激轴的T细胞存活调控

909

2026-04-21

【应用方向】LILRB家族:髓系细胞免疫检查点的研究前沿与产品解决方案

1242

2026-04-21

【应用方向】LAG-3(CD223):T细胞耗竭调控网络的核心节点

1127

2026-04-21

【应用方向】B7-H3(CD276):双重功能免疫检查点的分子特征与科研应用

1785

2026-04-20

【应用方向】HER2靶点蛋白:驱动肿瘤靶向治疗的核心力量

14909

2026-03-02

【技术讲解】细胞因子科学选型--常见问题解答

11523

2026-09-21

联系我们
购物车
客服
转染试用